C&G Editor in Chief, Erin Harris

  1. Building Antigen-Specific Immune Tolerance For Autoimmune Disease 8/10/2026

    Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.

  2. Solving Vector Yield Challenges Starts Long Before Manufacturing 7/22/2026

    Cell & Gene Live panelists take a deep dive into why solving vector yield challenges begins with early biological and manufacturing decisions rather than process optimization alone.

  3. Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors 7/17/2026

    US WorldMeds' expanded FDA approval for TECELRA represents another important step forward for engineered cell therapies in solid tumors.

  4. FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy 7/9/2026

    Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.

  5. How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale 6/29/2026

    Our latest Cell & Gene Live examined how CGT developers can choose manufacturing models that support long-term commercial success by aligning biology, operations, supply chain, and scalability from the earliest stages of development.

  6. In Vivo Gene Editing Is Moving From Promise To Proof 6/15/2026

    CGT is shifting from technical promise to clinical execution as in vivo approaches reach an inflection point where delivery, durability, specificity, and manufacturability will determine whether the field can turn breakthrough science into safe, scalable, repeatable therapies.

  7. Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT 6/2/2026

    Gene therapy’s next test is not proving it works, but proving it can scale.

  8. CGT Manufacturing Shifts From Capacity To Strategy 5/21/2026

    As manufacturing overcapacity reshapes the CGT landscape, success now depends less on access to capacity and more on strategic alignment across development, regulatory readiness, and long-term commercialization.

  9. Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook 5/13/2026

    At the 2026 @Philly Cell and Gene Therapy Annual Conference, Dr. Peter Marks highlighted how gene therapy science is surging ahead and called for smarter regulatory evolution to unlock treatments for thousands of rare disease patients.

  10. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.